Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study (Q34608783)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

type 2 diabetes

0 references

0 references

cardiovascular disease

1 reference

based on heuristic

inferred from title

A Michael Lincoff

2

object named as

A Michael Lincoff

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Robert R Henry

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sunder Mudaliar

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Michael Rabbia

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Cathy Chognot

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Matthias Herz

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

8 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

374

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

9684

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

126-135

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PPAR dual agonists: are they opening Pandora's Box?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960870-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60870-9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34608783&oldid=1634884571"